ALENDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+3
AUROBINDO PHARM
Drug class
Bisphosphonates
Bisphosphonates are a therapeutic class of antiresorptive medications structurally analogous to inorganic pyrophosphate that bind directly to hydroxyapatite crystals in the bone matrix. Read more about Bisphosphonates
73 drugs in this class 47 manufacturers
Drugs in Bisphosphonates
IBANDRONATE SODIUM
HYPERCALCEMIA AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
APOTEX CORP
ALENDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+3
NORTHSTAR RX LL
ALENDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+3
SUN PHARMA GLOB
IBANDRONATE SODIUM
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
DR.REDDY'S LAB
ZOLEDRONIC ACID
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+2
SUN PHARMA GLOB
ZOLEDRONIC ACID
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+2
SAGENT PHARMACE
ZOLEDRONIC ACID
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+2
SUN PHARMA GLOB
ZOLEDRONIC ACID
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+2
DR.REDDY'S LAB
Filter & compare in the drug finder →
Opens the drug finder with Bisphosphonates preselected. Add indication or manufacturer filters there.
Bisphosphonates are a therapeutic class of antiresorptive medications structurally analogous to inorganic pyrophosphate that bind directly to hydroxyapatite crystals in the bone matrix.
They exert their therapeutic effects primarily by inhibiting osteoclast-mediated bone resorption and accelerating osteoclast apoptosis, with newer nitrogen-containing agents specifically inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway.
Clinically, bisphosphonates are indicated for metabolic and oncologic skeletal disorders characterized by excessive bone turnover, notably postmenopausal and glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignancy, and solid tumor or multiple myeloma bone metastases.
-
nih.gov
Bisphosphonates are a therapeutic class of antiresorptive medications structurally analogous to inorganic pyrophosphate that bind directly to hydroxyapatite crystals in the bone matrix Clinically, bisphosphonates are indicated for metabolic and oncologic skeletal disorders characterized by excessive bone turnover, notably postmenopausal and glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignancy, and solid tumor or multiple myeloma bone metastases
-
nih.gov
Bisphosphonates are a therapeutic class of antiresorptive medications structurally analogous to inorganic pyrophosphate that bind directly to hydroxyapatite crystals in the bone matrix
-
nih.gov
Bisphosphonates are a therapeutic class of antiresorptive medications structurally analogous to inorganic pyrophosphate that bind directly to hydroxyapatite crystals in the bone matrix
-
nih.gov
They exert their therapeutic effects primarily by inhibiting osteoclast-mediated bone resorption and accelerating osteoclast apoptosis, with newer nitrogen-containing agents specifically inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway
-
nih.gov
They exert their therapeutic effects primarily by inhibiting osteoclast-mediated bone resorption and accelerating osteoclast apoptosis, with newer nitrogen-containing agents specifically inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway
-
nih.gov
They exert their therapeutic effects primarily by inhibiting osteoclast-mediated bone resorption and accelerating osteoclast apoptosis, with newer nitrogen-containing agents specifically inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway Clinically, bisphosphonates are indicated for metabolic and oncologic skeletal disorders characterized by excessive bone turnover, notably postmenopausal and glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignanc...
-
clevelandclinic.org
Clinically, bisphosphonates are indicated for metabolic and oncologic skeletal disorders characterized by excessive bone turnover, notably postmenopausal and glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignancy, and solid tumor or multiple myeloma bone metastases
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.